Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow, leading to the buildup of abnormal lymphocytes. It is the most common form of leukemia in adults. While genetic markers help with chemoimmunotherapy, new markers are needed for targeted therapies.
A multinational team of researchers, with first-author Dr Stephen Chong Jun Fei from N2CR, used BH3-profiling and various genetic and molecular data to find new treatment response markers. In 73 CLL patients, higher dependence on the BCL-2 protein was linked to better genetic markers and drug sensitivity. This was confirmed in cell studies and additional patients, showing BCL-2 dependence predicted positive treatment responses. BCL-2 dependence could be a useful marker for predicting CLL treatment response, helping to tailor therapies more effectively.
Click here to read more.
